<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2020.591713</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Distinct Roles of IL-1&#x3b2; and IL-18 in NLRC4-Induced Autoinflammation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Sasaki</surname>
<given-names>Yuki</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1061843"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Otsuka</surname>
<given-names>Kunihiro</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1052143"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arimochi</surname>
<given-names>Hideki</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1102833/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tsukumo</surname>
<given-names>Shin-Ichi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/504364"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Yasutomo</surname>
<given-names>Koji</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/30306"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Immunology and Parasitology, Graduate School of Medicine, Tokushima University</institution>, <addr-line>Tokushima</addr-line>, <country>Japan</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Interdisciplinary Researches for Medicine and Photonics, Institute of Post-LED Photonics, Tokushima University</institution>, <addr-line>Tokushima</addr-line>, <country>Japan</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>The Research Cluster Program on Immunological Diseases, Tokushima University</institution>, <addr-line>Tokushima</addr-line>, <country>Japan</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Seth Lucian Masters, Walter and Eliza Hall Institute of Medical Research, Australia</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Scott W. Canna, University of Pittsburgh Medical Center, United States; Si Ming Man, Australian National University, Australia</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Koji Yasutomo, <email xlink:href="mailto:yasutomo@tokushima-u.ac.jp">yasutomo@tokushima-u.ac.jp</email>
</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Autoimmune and Autoinflammatory Disorders, a section of the journal Frontiers in Immunology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>14</day>
<month>10</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>11</volume>
<elocation-id>591713</elocation-id>
<history>
<date date-type="received">
<day>05</day>
<month>08</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>09</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2020 Sasaki, Otsuka, Arimochi, Tsukumo and Yasutomo</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Sasaki, Otsuka, Arimochi, Tsukumo and Yasutomo</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>The NLRC4 inflammasome assembles in response to detection of bacterial invasion, and NLRC4 activation leads to the production of IL-1&#x3b2; and IL-18 together with pyroptosis-mediated cell death. Missense activating mutations in <italic>NLRC4</italic> cause autoinflammatory disorders whose symptoms are distinctly dependent on the site of mutation and other aspects of the genetic background. To determine the involvement of IL-1&#x3b2; and IL-18 in the inflammation induced by <italic>NLRC4</italic> mutation, we depleted IL-1&#x3b2;, IL-18, or both cytokines in Nlrc4-transgenic mice in which mutant <italic>Nlrc4</italic> is expressed under the MHC class II promoter (Nlrc4-H443P-Tg mice). The deletion of the <italic>Il1b</italic> or <italic>Il18</italic> gene in Nlrc4-H443P-Tg mice reduced the neutrophil numbers in the spleen, and mice with deletion of both genes had an equivalent number of neutrophils compared to wild-type mice. Deletion of <italic>Il1b</italic> ameliorated but did not eliminate bone marrow hyperplasia, while mice deficient in <italic>Il18</italic> showed no bone marrow hyperplasia. In contrast, tail bone deformity remained in the presence of <italic>Il18</italic> deficiency, but <italic>Il1b</italic> deficiency completely abolished bone deformity. The decreased bone density in Nlrc4-H443P-Tg mice was counteracted by <italic>Il1b</italic> but not <italic>Il18</italic> deficiency. Our results demonstrate the distinct effects of IL-1&#x3b2; and IL-18 on NLRC4-induced inflammation among tissues, which suggests that blockers for each cytokine should be utilized depending on the site of inflammation.</p>
</abstract>
<kwd-group>
<kwd>autoinflammation</kwd>
<kwd>NLRC4</kwd>
<kwd>interleukin-1&#x3b2;</kwd>
<kwd>interleukin-18</kwd>
<kwd>bone</kwd>
</kwd-group>
<counts>
<fig-count count="4"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="30"/>
<page-count count="7"/>
<word-count count="2931"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Inflammasomes are composed of an assembler protein such as a nucleotide-binding domain-containing proteins, a leucine-rich family protein, ASC and caspase-1, and inflammasome stimulation leads to the maturation and secretion of the IL-1&#x3b2; and IL-18 cytokines (<xref ref-type="bibr" rid="B1">1</xref>&#x2013;<xref ref-type="bibr" rid="B3">3</xref>). Inflammasome activation is induced by pathogen-associated molecular patterns as well as damage-associated molecular patterns. The activation of the inflammasome is accompanied by pyroptosis-mediated cell death, which causes burst secretion of IL-1&#x3b2; and IL-18 (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B4">4</xref>).</p>
<p>Hyperactivation of inflammasomes causes several types of diseases called autoinflammatory disorders (<xref ref-type="bibr" rid="B5">5</xref>&#x2013;<xref ref-type="bibr" rid="B8">8</xref>). <italic>NLRP3</italic> mutations were initially reported in cryopyrin-associated periodic fever syndrome (CAPS), which includes familial cold autoinflammatory syndrome, Muckle-Wells syndrome and neonatal-onset multisystem inflammatory disease (<xref ref-type="bibr" rid="B7">7</xref>). The NLRC4 inflammasome is activated by flagellin and two components of the type III secretion system, the rod and needle proteins, which directly interact with NAIP proteins in a receptor&#x2013;ligand fashion (<xref ref-type="bibr" rid="B9">9</xref>&#x2013;<xref ref-type="bibr" rid="B14">14</xref>). Once the NAIP protein binds its specific ligand, it can bind to NLRC4, leading to NLRC4 oligomerization (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>). Hyperactivation of NLRC4 by genetic mutation causes autoinflammatory disorders characterized by CAPS, enterocolitis, or macrophage activation syndrome (<xref ref-type="bibr" rid="B15">15</xref>&#x2013;<xref ref-type="bibr" rid="B18">18</xref>), which we hereafter call NLRC4-dysregulated diseases. Patients with mutations in <italic>NLRC4</italic> exhibit increases in IL-18 and IL-1&#x3b2; compared to patients with diseases associated with mutations in <italic>NLRP3</italic>. Indeed, blockade of IL-18 by IL-18BP ameliorates disease severity in patients with <italic>NLRC4</italic> mutations (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>).</p>
<p>Here, we assessed the contributions of IL-1&#x3b2; and IL-18 to NLRC4-dysregulated disorders. Mice that harbor a hyperactive <italic>Nlrc4</italic> gene spontaneously develop inflammation in the skin, liver and bone with an increased number of neutrophils in the spleen (<xref ref-type="bibr" rid="B15">15</xref>). As reported here, deletion of the <italic>Il1b</italic> gene partially ameliorated bone marrow inflammation and reduced serum IL-18. The deletion of <italic>Il18</italic> completely abolished bone marrow inflammation. In contrast, <italic>Il1b</italic> but not <italic>Il18</italic> deficiency abolished tail bone deformity and reduced bone density. These data demonstrate the distinct roles of IL-1&#x3b2; and IL-18 in NLRC4-dysregulated diseases and reveal that blockade of both IL-18 and IL-1&#x3b2; is needed to completely suppress inflammation.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="s2_1">
<title>Mice</title>
<p>The Nlrc4-H443P-Tg mice, <italic>Il1b</italic>-deficient mice, and <italic>Il18</italic>-deficient mice have been previously reported (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>). All mice were maintained under specific pathogen-free conditions in the animal facilities at Tokushima University, Japan. All experiments were performed in accordance with institutional guidelines and the animal care research committee at Tokushima University.</p>
</sec>
<sec id="s2_2">
<title>ELISA</title>
<p>Cytokines in the serum were analyzed using a Mouse G-CSF Quantikine ELISA kit (catalog #MCS00) and mouse IL-18/IL-1F4 ELISA kit (catalog #7625) according to the manufacturer&#x2019;s instructions (R&amp;D Systems, MN, USA).</p>
</sec>
<sec id="s2_3">
<title>Flow Cytometry</title>
<p>Spleen single-cell suspensions were obtained and treated with RBC lysis buffer. Cells were then incubated with rat anti-mouse CD16/CD32 Ab followed by mAbs specific for extracellular markers. Fluorochrome-conjugated monoclonal antibodies specific for mouse TCR&#x3b2; (H57-597), CD19 (1D3), CD11b (M1/70), and Gr-1 (RB6-8C5) were purchased from BioLegend (San Diego, CA, USA). Neutrophils were identified as CD11b<sup>+</sup>Gr-1<sup>high</sup> cells. Data were collected on a FACS Canto II (BD Biosciences) flow cytometer and analyzed using FACS Diva (BD Biosciences) or FlowJo (Tree Star, OR, USA) software.</p>
</sec>
<sec id="s2_4">
<title>Histology</title>
<p>Ear skin samples were collected and fixed in 10% formalin solution. Bone tissues were fixed in 10% formalin and then demineralized in 10% EDTA. The samples were sectioned and stained with H&amp;E and evaluated with respect to cell influx and edema (0, no influx or edema; 1, mild influx and edema; 2, moderate influx and edema; and 3, severe influx and edema) and bone marrow hyperplasia and bone deformity (0, no hyperplasia or deformity; 1, mild hyperplasia and deformity; 2, moderate hyperplasia and deformity; and 3, severe hyperplasia and deformity) by semiquantitative examination.</p>
</sec>
<sec id="s2_5">
<title>Computed Tomography</title>
<p>The left foot and tail were analyzed <italic>in vivo</italic> with microcomputerized tomography at high resolution. The bone density of lower limbs was calculated using Latheta software (Latheta LCT-200, Hitachi Aloka Medical, Tokyo, Japan) 3D morphology reconstruction was performed using 3D Slicer (version 4.10.2). The 3D sections of paw and tail evaluated with respect to bone deformity (0, no deformity, 1, mild; 2, moderate; and 3, severe deformity) by semiquantitative examination.</p>
</sec>
<sec id="s2_6">
<title>Statistical Analysis</title>
<p>For all experiments, the significant differences between groups were calculated using Student&#x2019;s <italic>t</italic>-test for unpaired data or one-way ANOVA. Differences were considered significant when <italic>p</italic> &lt; 0.05.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>Both IL-1&#x3b2; and IL-18 Are Required for Inflammation in Nlrc4-H443P-Tg Mice</title>
<p>To assess the involvement of IL-1&#x3b2; and IL-18 in Nlrc4-H443P-Tg mice, we crossed Nlrc4-H443P-Tg mice with <italic>Il1b-</italic> or <italic>Il18</italic>-deficient (Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup> or Nlrc4-H443P-Tg/Il18<sup>&#x2212;/&#x2212;</sup>, respectively) mice or with mice deficient in both genes (Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>Il18<sup>&#x2212;/&#x2212;</sup>). We have previously reported that Nlrc4-H443P-Tg mice have an increased number of CD11b<sup>+</sup>Gr-1<sup>high</sup> neutrophils in the spleen (<xref ref-type="bibr" rid="B15">15</xref>). We first evaluated the number of CD11b<sup>+</sup>Gr-1<sup>high</sup> neutrophils in the spleens of Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>, Nlrc4-H443P-Tg/Il18<sup>&#x2212;/&#x2212;</sup>, and Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>Il18<sup>&#x2212;/&#x2212;</sup> mice at 8 weeks (<xref ref-type="fig" rid="f1">
<bold>Figure 1A</bold>
</xref>). The number of CD11b<sup>+</sup>Gr-1<sup>high</sup> neutrophils at 8 weeks was comparable among control, Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>, Nlrc4-H443P-Tg/Il18<sup>&#x2212;/&#x2212;</sup>, and Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>Il18<sup>&#x2212;/&#x2212;</sup> mice (<xref ref-type="fig" rid="f1">
<bold>Figure 1A</bold>
</xref>). An increase in CD11b<sup>+</sup>Gr-1<sup>high</sup> neutrophils was detected in Nlrc4-H443P-Tg mice at 20 weeks (<xref ref-type="fig" rid="f1">
<bold>Figure 1B</bold>
</xref>). The number of CD11b<sup>+</sup>Gr-1<sup>high</sup> neutrophils was reduced in both Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup> and Nlrc4-H443P-Tg/Il18<sup>&#x2212;/&#x2212;</sup> mice, and the number in Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>Il18<sup>&#x2212;/&#x2212;</sup> mice was almost equivalent to that in wild-type mice (<xref ref-type="fig" rid="f1">
<bold>Figure 1B</bold>
</xref>). The number of T cells and B cells are also increased in Nlrc4-H443P-Tg mice, which was reduced in the absence of IL-1&#x3b2; and IL-18 (<xref ref-type="fig" rid="f1">
<bold>Figure 1B</bold>
</xref>). In further experiments, to analyze the effect of IL-1&#x3b2; and IL-18, we used mice at the age of 20 weeks.</p>
<fig id="f1" position="float">
<label>Figure 1</label>
<caption>
<p>IL-1&#x3b2;&#x2013; and Il-18&#x2013;mediated inflammation in Nlrc4-H443P-Tg mice. <bold>(A)</bold> Total neutrophil numbers in the spleens of control, Nlrc4-H443P-Tg, Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>, Nlrc4-H443P-Tg/Il18<sup>&#x2212;/&#x2212;</sup>, and Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>Il18<sup>&#x2212;/&#x2212;</sup> mice at the age of 8 and weeks were determined (N = 8 in each group). The neutrophils were defined as CD11b+Gr-1<sup>high</sup> cells. The data are shown as the mean &#xb1; SD. *P &lt; 0.05; **P &lt; 0.01. <bold>(B)</bold> Total neutrophil, T cells or B cells numbers in the spleens of control, Nlrc4-H443P-Tg, Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>, Nlrc4-H443P-Tg/Il18<sup>&#x2212;/&#x2212;</sup>, and Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>Il18<sup>&#x2212;/&#x2212;</sup> mice at the age of 20 weeks were determined (N = 8 in each group). The data are shown as the mean &#xb1; SD. *P &lt; 0.05; **P &lt; 0.01. Serum <bold>(C)</bold> IL-18 was measured in control, Nlrc4-H443P-Tg, Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup> and Nlrc4-H443P-Tg/Il18<sup>&#x2212;/&#x2212;</sup> mice at the age of 20 weeks (N = 5 in each group), and serum <bold>(D)</bold> G-CSF was measured in control, Nlrc4-H443P-Tg, Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>, Nlrc4-H443P-Tg/Il18<sup>&#x2212;/&#x2212;</sup>, and Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>Il18<sup>&#x2212;/&#x2212;</sup> mice at the age of 20 weeks (N = 5 in each group). Data are shown as the mean &#xb1; SD. **P &lt; 0.01.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-11-591713-g001.tif"/>
</fig>
<p>We next tested the serum levels of cytokines in mice at the age of 20 weeks. IL-18 was increased in the Nlrc4-H443P-Tg mice, and <italic>Il1b</italic> deficiency reduced the level (<xref ref-type="fig" rid="f1">
<bold>Figure 1C</bold>
</xref>), indicating that the increase in IL-18 is partially dependent on IL-1&#x3b2;. The serum G-CSF level was also increased in the Nlrc4-H443P-Tg mice, and deficiency in either <italic>Il1b</italic> or <italic>Il18</italic> reduced the level, whereas deletion of both led to a level equivalent to that in control mice (<xref ref-type="fig" rid="f1">
<bold>Figure 1D</bold>
</xref>).</p>
</sec>
<sec id="s3_2">
<title>Blockade of IL-1&#x3b2; or IL-18 Ameliorates Inflammation in Nlrc4-H443P-Tg Mice</title>
<p>We next analyzed the histology of ear skin, joint and bone marrow samples from control, Nlrc4-H443P-Tg, Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>, Nlrc4-H443P-Tg/Il18<sup>&#x2212;/&#x2212;</sup>, and Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>Il18<sup>&#x2212;/&#x2212;</sup> mice (<xref ref-type="fig" rid="f2">
<bold>Figures 2A, B</bold>
</xref>). The Nlrc4-H443P-Tg mice showed massive infiltration of immune cells in the ear skin, joint and bone marrow samples. The skin in Nlrc4-H443P-Tg mice was thickened because of edema compared with that in wild-type mice. Deletion of either <italic>Il1b</italic> or <italic>Il18</italic> ameliorated cell infiltration in the skin and joints (<xref ref-type="fig" rid="f2">
<bold>Figures 2A, B</bold>
</xref>). In contrast, deletion of <italic>Il18</italic> almost completely abolished hyperplasia in the bone marrow, while mice deficient in <italic>Il1b</italic> still exhibited moderate hyperplasia in the bone marrow. Deletion of both <italic>Il1b</italic> and <italic>Il18</italic> completely abolished inflammation in any tissues (<xref ref-type="fig" rid="f2">
<bold>Figures 2A, B</bold>
</xref>). These data indicate that both IL-1&#x3b2; and IL-18 are responsible for inflammation in Nlrc4-H443P-Tg mice and that IL-18 has a greater impact on bone marrow inflammation than IL-1&#x3b2;.</p>
<fig id="f2" position="float">
<label>Figure 2</label>
<caption>
<p>IL-1&#x3b2;&#x2013; and Il-18&#x2013;mediated inflammation in the skin and joints of Nlrc4-H443P-Tg mice. <bold>(A)</bold> Histological sections of ear skin and ankle joints in control, Nlrc4-H443P-Tg, Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>, Nlrc4-H443P-Tg/Il18<sup>&#x2212;/&#x2212;</sup>, and Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>Il18<sup>&#x2212;/&#x2212;</sup> mice at the age of 20 weeks were stained with hematoxylin and eosin. <bold>(B)</bold> The histological scores were evaluated in the ear skin and ankle joints in in control, Nlrc4-H443P-Tg, Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>, Nlrc4-H443P-Tg/Il18<sup>&#x2212;/&#x2212;</sup>, and Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>Il18<sup>&#x2212;/&#x2212;</sup> mice at the age of 20 weeks (N = 8 in each group). Data are shown as the mean &#xb1; SD. *P &lt; 0.05, **P &lt; 0.01.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-11-591713-g002.tif"/>
</fig>
</sec>
<sec id="s3_3">
<title>Blockade of IL-1&#x3b2; Is More Effective Than That of IL-18 in Treating Bone Erosion in Nlrc4-H443P-Tg Mice</title>
<p>We assessed the shapes of bones in the left foot and tail using &#x3bc;CT analysis to evaluate the effect of IL-1&#x3b2; or IL18 on the bone phenotype of Nlrc4-H443P-Tg mice (<xref ref-type="fig" rid="f3">
<bold>Figure 3</bold>
</xref>). Bone deformity was also observed in vertebrae (data not shown). Nlrc4-H443P-Tg mice developed severe deformities of the left foot and tail with narrowing of the joint cavity. Deficiency in <italic>Il1b</italic> or <italic>Il18</italic> completely diminished the deformity in the foot bones and joints. In contrast, mice deficient in <italic>Il18</italic> showed mild deformity in the tail bones, while <italic>Il1b</italic>-deficient mice exhibited no tail bone deformity (<xref ref-type="fig" rid="f3">
<bold>Figure 3</bold>
</xref>).</p>
<fig id="f3" position="float">
<label>Figure 3</label>
<caption>
<p>IL-1&#x3b2;&#x2013; and Il-18&#x2013;mediated bone deformity in Nlrc4-H443P-Tg mice. The tail and left foot in control, Nlrc4-H443P-Tg, Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>, Nlrc4-H443P-Tg/Il18<sup>&#x2212;/&#x2212;</sup>, and Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>Il18<sup>&#x2212;/&#x2212;</sup> mice at the age of 20 weeks were evaluated with &#x3bc;CT. Red arrows, bone deformity regions (N = 5 in each group). The scores were evaluated as shown in the Materials and Methods in control, Nlrc4-H443P-Tg, Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>, Nlrc4-H443P-Tg/Il18<sup>&#x2212;/&#x2212;</sup>, and Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>Il18<sup>&#x2212;/&#x2212;</sup> mice at the age of 20 weeks (N = 8 in each group). Data are shown as the mean &#xb1; SD. **P &lt; 0.01.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-11-591713-g003.tif"/>
</fig>
<p>Bone density was also decreased in Nlrc4-H443P-Tg mice (<xref ref-type="fig" rid="f4">
<bold>Figure 4</bold>
</xref>). <italic>Il1b</italic> deficiency completely rescued the reduced bone density in Nlrc4-H443P-Tg mice, while <italic>Il18</italic> deficiency partially reversed this reduction (<xref ref-type="fig" rid="f4">
<bold>Figure 4</bold>
</xref>). These data suggest that IL-1&#x3b2; has more important roles in bone phenotypes than IL-18 in NLRC4-dysregulated diseases.</p>
<fig id="f4" position="float">
<label>Figure 4</label>
<caption>
<p>Rescue of decreased bone density by deficiency of Il1b or Il18 in Nlrc4-H443P-Tg mice. Bone density in control, Nlrc4-H443P-Tg, Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>, Nlrc4-H443P-Tg/Il18<sup>&#x2212;/&#x2212;</sup>, and Nlrc4-H443P-Tg/Il1b<sup>&#x2212;/&#x2212;</sup>Il18<sup>&#x2212;/&#x2212;</sup> mice at the age of 20 weeks was evaluated with &#x3bc;CT (N = 10 in each group). The data are shown as the mean &#xb1; SD. *P &lt; 0.05, **P &lt; 0.01.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-11-591713-g004.tif"/>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>Heterozygous mutations in <italic>NLRC4</italic> cause several types of autoinflammatory disorders. For instance, <italic>NLRC4</italic> mutations cause CAPS-like syndrome, including cold-induced autoinflammatory syndrome and NOMID (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B18">18</xref>). The clinical phenotypes of CAPS-like syndrome caused by <italic>NLRC4</italic> mutations are indistinguishable from those caused by <italic>NLRP3</italic> mutations. <italic>NLRC4</italic> mutations also cause infantile enteritis and macrophage activation syndrome (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>). One of the characteristics of NLRC4-dysregulated diseases is high serum IL-18, and IL-18 blockade is effective in treating macrophage activation syndrome caused by <italic>NLRC4</italic> mutation (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>). However, the roles of IL-18 and IL-1&#x3b2; in NLRC4-dysregulated diseases are not fully understood, and thus, we tested the roles of each cytokine by using mice in which a mutant <italic>Nlrc4</italic> is expressed under the MHC class II promoter in combination with <italic>Il1b</italic> and <italic>Il18</italic> deficiency. Our data demonstrated the distinct roles of IL-1&#x3b2; and IL-18 in inflammation in the joints and skin, suggesting that the efficacy of blockers of each cytokine depends on the regions of inflammation.</p>
<p>Blockade of IL-1&#x3b2; and Il-18 is effective for ameliorating inflammation in Nlrc4-H443P-Tg mice, although the contribution of each cytokine to inflammation is distinct among tissues. Induced deficiency of <italic>Il18</italic> is more effective than that of <italic>Il1b</italic> in suppressing bone marrow hyperplasia, and <italic>Il1b</italic> deficiency better inhibited bone deformity and decreases in bone density than <italic>Il18</italic> deficiency. One possibility to explain the distinct effects of these cytokines in tissues would be differences in the cell types that respond to IL-1&#x3b2; or IL-18. In any case, our data suggest that the blockade of both IL-1&#x3b2; and IL-18 is required to completely suppress inflammation in NLRC4-dysregulated diseases. In addition, Nlrc4-H443P-Tg mice with deletion of both <italic>Il1b</italic> and <italic>Il18</italic> do not show any inflammation or any increase in neutrophils, suggesting a small contribution of pyroptosis-mediated cell death and cell death-associated damage-associated molecular patterns to inflammation in NLRC4-dysregulated diseases.</p>
<p>NOMID patients exhibit bone deformity accompanied by joint inflammation (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>). Nlrc4-H443P-Tg mice also show severe bone deformity at the age of 20 weeks. Bone deformity is caused by IL-1&#x3b2; and IL-18, but blockade of IL-18 is not enough to suppress the deformity. On the other hand, recent studies have indicated that the blockade of IL-18 is effective in treating macrophage activation syndrome caused by <italic>NLRC4</italic> mutation that is refractory to blockade of IL-1&#x3b2;. Our data suggest that bone phenotypes in NLRC4-associated NOMID might be treated with a combination of blockers of IL-1&#x3b2; and IL-18. Regarding the contribution of IL-1&#x3b2; and IL-18 to bone deformity, a previous study demonstrated that IL-18 upregulates membrane-bound receptor activator of nuclear factor kappa B ligand (RANKL) expression and soluble RANKL production, thus increasing the ratio of RANKL/osteoprotegerin, suggesting an effect of IL-18 on the induction of osteoclast formation and bone resorption (<xref ref-type="bibr" rid="B25">25</xref>). IL-1&#x3b2; is involved in osteoclast differentiation in part through the induction of TRAF-6 downstream of the IL-1&#x3b2; pathway (<xref ref-type="bibr" rid="B26">26</xref>). Further studies are required to clarify not only the molecular mechanism of IL-1&#x3b2;-mediated bone deformity but also the roles of IL-18 in this context.</p>
<p>Several gene-modified mice were reported to investigate the molecular mechanisms of autoinflammatory disorders including CAPS. Pyrin-knock-in mice harboring mutant human B30.2 domains exhibited spontaneous bone marrow-dependent inflammation similar to that seen in human familial Mediterranean fever (<xref ref-type="bibr" rid="B27">27</xref>). This inflammation was completely abrogated in the absence of the IL-1 receptor or the adaptor molecule ASC. Nlrp3-knock-in mice demonstrated early mortality mediated by myeloid cells, which was only partially dependent on IL-1&#x3b2; (<xref ref-type="bibr" rid="B28">28</xref>). Deletion of <italic>Il18r</italic> in Nlrp3-knock-in mice resulted in partial phenotypic rescue in skin and visceral disease and reduced serum cytokines (<xref ref-type="bibr" rid="B29">29</xref>). Another strain of Nlrp3-knock-in mice exhibited skin inflammation with neutrophil infiltration and a Th17 cytokine-dominant response, which was suppressed in the absence of the IL-1 receptor (<xref ref-type="bibr" rid="B30">30</xref>). The comparison of our Nlrc4-H443P-Tg mice with the pyrin- or Nlrp3-knock-in mice side by side would be interesting to understand the effect of each cytokine on organ pathology induced by <italic>NLRC4</italic> mutations.</p>
<p>In summary, our data demonstrate the crucial contributions of IL-1&#x3b2; and IL-18 to NLRC4-dysregulated diseases but reveal that the two cytokines have distinct roles depending on the tissue. These data suggest that blockers of IL-1&#x3b2; and IL-18 should be utilized depending on the site of tissue inflammation in NLRC4-dysregulated diseases.</p>
</sec>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s6">
<title>Ethics Statement</title>
<p>The animal study was reviewed and approved by animal care research committee at Tokushima University.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>YS and KY designed the studies. YS, KO, SI T, and HA analyzed the data. YS and KY wrote the paper. KY supervised all studies. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>The research is supported by The Research Cluster Program on Immunological Diseases, Tokushima University</p>
</sec>
<sec id="s9">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We thank C. Kinouchi, K. Takahashi, and A. Kitamura for their technical assistance.</p>
</ack>
<sec id="s10" sec-type="supplementary-material">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2020.591713/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2020.591713/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet_1.pdf" id="SF1" mimetype="application/pdf">
<label>Supplementary Figure 1</label>
<caption>
<p>
<italic>Gating strategy for detecting neutrophils</italic>. Total spleen cells were stained with 7AAD, anti-CD11b and Gr-1 antibodies. In the singlet and 7AAD negative populations, CD11b+Gr-1<sup>high</sup> cells were defined as neutrophils.</p>
</caption>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinon</surname> <given-names>F</given-names>
</name>
<name>
<surname>Mayor</surname> <given-names>A</given-names>
</name>
<name>
<surname>Tschopp</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>The inflammasomes: guardians of the body</article-title>. <source>Annu Rev Immunol</source> (<year>2009</year>) <volume>27</volume>:<page-range>229&#x2013;65</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1146/annurev.immunol.021908.132715</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>GY</given-names>
</name>
<name>
<surname>Nunez</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Sterile inflammation: sensing and reacting to damage</article-title>. <source>Nat Rev Immunol</source> (<year>2010</year>) <volume>10</volume>:<page-range>826&#x2013;37</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri2873</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Broz</surname> <given-names>P</given-names>
</name>
<name>
<surname>Dixit</surname> <given-names>VM</given-names>
</name>
</person-group>. <article-title>Inflammasomes: mechanism of assembly, regulation and signalling</article-title>. <source>Nat Rev Immunol</source> (<year>2016</year>) <volume>16</volume>:<page-range>407&#x2013;20</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri.2016.58</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kesavardhana</surname> <given-names>S</given-names>
</name>
<name>
<surname>Malireddi</surname> <given-names>RKS</given-names>
</name>
<name>
<surname>Kanneganti</surname> <given-names>TD</given-names>
</name>
</person-group>. <article-title>Caspases in Cell Death, Inflammation, and Pyroptosis</article-title>. <source>Annu Rev Immunol</source> (<year>2020</year>) <volume>38</volume>:<page-range>567&#x2013;95</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1146/annurev-immunol-073119-095439</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aksentijevich</surname> <given-names>I</given-names>
</name>
<name>
<surname>Kastner</surname> <given-names>DL</given-names>
</name>
</person-group>. <article-title>Genetics of monogenic autoinflammatory diseases: past successes, future challenges</article-title>. <source>Nat Rev Rheumatol</source> (<year>2011</year>) <volume>7</volume>:<page-range>469&#x2013;78</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrrheum.2011.94</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Jesus</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Canna</surname> <given-names>SW</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Goldbach-Mansky</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling</article-title>. <source>Annu Rev Immunol</source> (<year>2015</year>) <volume>33</volume>:<page-range>823&#x2013;74</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1146/annurev-immunol-032414-112227</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manthiram</surname> <given-names>K</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Aksentijevich</surname> <given-names>I</given-names>
</name>
<name>
<surname>Kastner</surname> <given-names>DL</given-names>
</name>
</person-group>. <article-title>The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation</article-title>. <source>Nat Immunol</source> (<year>2017</year>) <volume>18</volume>:<page-range>832&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ni.3777</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gattorno</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hofer</surname> <given-names>M</given-names>
</name>
<name>
<surname>Federici</surname> <given-names>S</given-names>
</name>
<name>
<surname>Vanoni</surname> <given-names>F</given-names>
</name>
<name>
<surname>Bovis</surname> <given-names>F</given-names>
</name>
<name>
<surname>Aksentijevich</surname> <given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Classification criteria for autoinflammatory recurrent fevers</article-title>. <source>Ann Rheum Dis</source> (<year>2019</year>) <volume>78</volume>:<page-range>1025&#x2013;32</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/annrheumdis-2019-215048</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kofoed</surname> <given-names>EM</given-names>
</name>
<name>
<surname>Vance</surname> <given-names>RE</given-names>
</name>
</person-group>. <article-title>Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity</article-title>. <source>Nature</source> (<year>2011</year>) <volume>477</volume>:<page-range>592&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature10394</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>J</given-names>
</name>
<name>
<surname>Gong</surname> <given-names>YN</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus</article-title>. <source>Nature</source> (<year>2011</year>) <volume>477</volume>:<fpage>596</fpage>&#x2013;<lpage>600</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature10510</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>J</given-names>
</name>
<name>
<surname>Shao</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Human NAIP and mouse NAIP1 recognize bacterial type III secretion needle protein for inflammasome activation</article-title>. <source>Proc Natl Acad Sci U.S.A.</source> (<year>2013</year>) <volume>110</volume>:<page-range>14408&#x2013;13</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.1306376110</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>J</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Shao</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Genetic functions of the NAIP family of inflammasome receptors for bacterial ligands in mice</article-title>. <source>J Exp Med</source> (<year>2016</year>) <volume>213</volume>:<page-range>647&#x2013;56</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.20160006</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fusco</surname> <given-names>WG</given-names>
</name>
<name>
<surname>Duncan</surname> <given-names>JA</given-names>
</name>
</person-group>. <article-title>Novel aspects of the assembly and activation of inflammasomes with focus on the NLRC4 inflammasome</article-title>. <source>Int Immunol</source> (<year>2018</year>) <volume>30</volume>:<page-range>183&#x2013;93</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/intimm/dxy009</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duncan</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Canna</surname> <given-names>SW</given-names>
</name>
</person-group>. <article-title>The NLRC4 Inflammasome</article-title>. <source>Immunol Rev</source> (<year>2018</year>) <volume>281</volume>:<page-range>115&#x2013;23</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/imr.12607</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kitamura</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sasaki</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Abe</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kano</surname> <given-names>H</given-names>
</name>
<name>
<surname>Yasutomo</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>An inherited mutation in NLRC4 causes autoinflammation in human and mice</article-title>. <source>J Exp Med</source> (<year>2014</year>) <volume>211</volume>:<page-range>2385&#x2013;96</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.20141091</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Canna</surname> <given-names>SW</given-names>
</name>
<name>
<surname>de Jesus</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Gouni</surname> <given-names>S</given-names>
</name>
<name>
<surname>Brooks</surname> <given-names>SR</given-names>
</name>
<name>
<surname>Marrero</surname> <given-names>B</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome</article-title>. <source>Nat Genet</source> (<year>2014</year>) <volume>46</volume>:<page-range>1140&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ng.3089</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Romberg</surname> <given-names>N</given-names>
</name>
<name>
<surname>Al Moussawi</surname> <given-names>K</given-names>
</name>
<name>
<surname>Nelson-Williams</surname> <given-names>C</given-names>
</name>
<name>
<surname>Stiegler</surname> <given-names>AL</given-names>
</name>
<name>
<surname>Loring</surname> <given-names>E</given-names>
</name>
<name>
<surname>Choi</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation</article-title>. <source>Nat Genet</source> (<year>2014</year>) <volume>46</volume>:<page-range>1135&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ng.3066</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawasaki</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Oda</surname> <given-names>H</given-names>
</name>
<name>
<surname>Ito</surname> <given-names>J</given-names>
</name>
<name>
<surname>Niwa</surname> <given-names>A</given-names>
</name>
<name>
<surname>Tanaka</surname> <given-names>T</given-names>
</name>
<name>
<surname>Hijikata</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Identification of a High-Frequency Somatic NLRC4 Mutation as a Cause of Autoinflammation by Pluripotent Cell-Based Phenotype Dissection</article-title>. <source>Arthritis Rheumatol</source> (<year>2017</year>) <volume>69</volume>:<page-range>447&#x2013;59</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/art.39960</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Novick</surname> <given-names>D</given-names>
</name>
<name>
<surname>Dinarello</surname> <given-names>CA</given-names>
</name>
</person-group>. <article-title>IL-18 binding protein reverses the life-threatening hyperinflammation of a baby with the NLRC4 mutation</article-title>. <source>J Allergy Clin Immunol</source> (<year>2017</year>) <volume>140</volume>:<fpage>316</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaci.2017.02.037</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Canna</surname> <given-names>SW</given-names>
</name>
<name>
<surname>Girard</surname> <given-names>C</given-names>
</name>
<name>
<surname>Malle</surname> <given-names>L</given-names>
</name>
<name>
<surname>de Jesus</surname> <given-names>A</given-names>
</name>
<name>
<surname>Romberg</surname> <given-names>N</given-names>
</name>
<name>
<surname>Kelsen</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition</article-title>. <source>J Allergy Clin Immunol</source> (<year>2017</year>) <volume>139</volume>:<page-range>1698&#x2013;701</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaci.2016.10.022</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horai</surname> <given-names>R</given-names>
</name>
<name>
<surname>Asano</surname> <given-names>M</given-names>
</name>
<name>
<surname>Sudo</surname> <given-names>K</given-names>
</name>
<name>
<surname>Kanuka</surname> <given-names>H</given-names>
</name>
<name>
<surname>Suzuki</surname> <given-names>M</given-names>
</name>
<name>
<surname>Nishihara</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion</article-title>. <source>J Exp Med</source> (<year>1998</year>) <volume>187</volume>:<page-range>1463&#x2013;75</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.187.9.1463</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takeda</surname> <given-names>K</given-names>
</name>
<name>
<surname>Tsutsui</surname> <given-names>H</given-names>
</name>
<name>
<surname>Yoshimoto</surname> <given-names>T</given-names>
</name>
<name>
<surname>Adachi</surname> <given-names>O</given-names>
</name>
<name>
<surname>Yoshida</surname> <given-names>N</given-names>
</name>
<name>
<surname>Kishimoto</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Defective NK cell activity and Th1 response in IL-18-deficient mice</article-title>. <source>Immunity</source> (<year>1998</year>) <volume>8</volume>:<page-range>383&#x2013;90</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s1074-7613(00)80543-9</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozen</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bilginer</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin</article-title>. <source>Nat Rev Rheumatol</source> (<year>2014</year>) <volume>10</volume>:<page-range>135&#x2013;47</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrrheum.2013.174</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuemmerle-Deschner</surname> <given-names>JB</given-names>
</name>
<name>
<surname>Ozen</surname> <given-names>S</given-names>
</name>
<name>
<surname>Tyrrell</surname> <given-names>PN</given-names>
</name>
<name>
<surname>Kone-Paut</surname> <given-names>I</given-names>
</name>
<name>
<surname>Goldbach-Mansky</surname> <given-names>R</given-names>
</name>
<name>
<surname>Lachmann</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS)</article-title>. <source>Ann Rheum Dis</source> (<year>2017</year>) <volume>76</volume>:<page-range>942&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/annrheumdis-2016-209686</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Cong</surname> <given-names>XL</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>YH</given-names>
</name>
<name>
<surname>He</surname> <given-names>ZW</given-names>
</name>
<name>
<surname>He</surname> <given-names>DY</given-names>
</name>
</person-group>. <article-title>Dai S.M. IL-18 upregulates the production of key regulators of osteoclastogenesis from fibroblast-like synoviocytes in rheumatoid arthritis</article-title>. <source>Inflammation</source> (<year>2013</year>) <volume>36</volume>:<page-range>103&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10753-012-9524-8</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choe</surname> <given-names>JY</given-names>
</name>
<name>
<surname>Park</surname> <given-names>KY</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>SK</given-names>
</name>
</person-group>. <article-title>Monosodium Urate in the Presence of RANKL Promotes Osteoclast Formation through Activation of c-Jun N-Terminal Kinase</article-title>. <source>Mediators Inflammation</source> (<year>2015</year>) <volume>2015</volume>:<elocation-id>597512</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2015/597512</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chae</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Cho</surname> <given-names>YH</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>GS</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>J</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>PP</given-names>
</name>
<name>
<surname>Feigenbaum</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation and severe autoinflammation in mice</article-title>. <source>Immunity</source> (<year>2011</year>) <volume>34</volume>:<page-range>755&#x2013;68</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2011.02.020</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brydges</surname> <given-names>SD</given-names>
</name>
<name>
<surname>Mueller</surname> <given-names>JL</given-names>
</name>
<name>
<surname>McGeough</surname> <given-names>MD</given-names>
</name>
<name>
<surname>Pena</surname> <given-names>CA</given-names>
</name>
<name>
<surname>Misaghi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Gandhi</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity</article-title>. <source>Immunity</source> (<year>2009</year>) <volume>30</volume>:<page-range>875&#x2013;87</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2009.05.005</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brydges</surname> <given-names>SD</given-names>
</name>
<name>
<surname>Broderick</surname> <given-names>L</given-names>
</name>
<name>
<surname>McGeough</surname> <given-names>MD</given-names>
</name>
<name>
<surname>Pena</surname> <given-names>CA</given-names>
</name>
<name>
<surname>Mueller</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Hoffman</surname> <given-names>HM</given-names>
</name>
</person-group>. <article-title>Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies</article-title>. <source>J Clin Invest</source> (<year>2013</year>) <volume>123</volume>:<page-range>4695&#x2013;705</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/JCI71543</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meng</surname> <given-names>G</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Fuss</surname> <given-names>I</given-names>
</name>
<name>
<surname>Kitani</surname> <given-names>A</given-names>
</name>
<name>
<surname>Strober</surname> <given-names>W</given-names>
</name>
</person-group>. <article-title>A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses</article-title>. <source>Immunity</source> (<year>2009</year>) <volume>30</volume>:<page-range>860&#x2013;74</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2009.04.012</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>